ENXTPA:IPNPharmaceuticals
Did Bylvay’s Expanded ALGS Approval Just Shift Ipsen's (ENXTPA:IPN) Rare Disease Investment Narrative?
Medison and Ipsen announced that Health Canada has approved Bylvay (odevixibat) for the treatment of cholestatic pruritus in patients 12 months and older with Alagille Syndrome (ALGS), expanding its use in Canada beyond its existing indication for PFIC.
This decision is backed by data from the Phase III ASSERT study, making Bylvay the first therapy supported by this level of clinical evidence for ALGS, and marks a significant development in addressing rare pediatric liver diseases.
Next,...